What are the potential implications of circulating biomarkers on the diagnosis of heart failure?
Circulating biomarkers have the potential to improve the diagnosis of heart failure. Studies have shown that biomarkers such as Galectin-3, ST2, growth differentiation factor-15, and highly-sensitive troponin T can be used to accurately identify patients with heart failure and predict long-term outcomes. These biomarkers also provide insight into the underlying pathology of heart failure, such as myocardial stress and fibrosis, which may be used to guide treatment decisions. Furthermore, recent studies have suggested that circulating microRNAs may have a role in the diagnosis and prognosis of heart failure.  